title: Efficacy, safety, and tolerability of intravesically administered 0.1% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: A randomized, prospective, controlled multi-center trial.
abstract: To verify the efficacy, safety and tolerability of intravesical administration of 0.1% oxybutynin hydrochloride compared to its oral administration for treatment of neurogenic detrusor overactivity (NDO) in a randomized, prospective, controlled, open-label, multi-center trial in 35 adult patients.
  
  
  
  NDO was confirmed within the previous 24 months by urodynamic studies (UDS). Group 1 (n = 18) received 10 ml 0.1% oxybutynin hydrochloride intravesically three times per day and group 2 (n = 17) 5 mg oxybutynin hydrochloride orally three times per day for a period of 28 days. Primary efficacy criterion was the change in the maximum bladder capacity between the beginning of the study and after 4 weeks as assessed by UDS. Adverse drug reactions (ADR) were collected and an evaluation of anticholinergic effects was conducted.
  
  
  
  The increase in maximum bladder capacity was 117 ml with intravesical application (P = 0.0002) versus 18 ml with the oral application (P = 0.51). The difference was statistically significant (P = 0.0086). ADR were reported by 10 (55.6%) of patients with intravesical administration, and by 14 (82.4%) of patients with oral administration. Significant differences in favor of the intravesical application were observed in ADR affecting vision (1/10 vs. 9/14), gastrointestinal tract (8/10 vs. 14/14), nervous system (2/10 vs. 8/14), and skin and subcutis (1/10 vs. 6/14). No serious adverse drug reactions were reported.
  
  
  
  This study demonstrates the efficacy and safety of intravesical 0.1% oxybutynin hydrochloride in the treatment of NDO with respect to the increase in maximum bladder capacity. Neurourol. Urodynam. 35:582-588, 2016. © 2015 Wiley Periodicals, Inc.
authors.affiliation: Division of Pediatric Urology, Department of Urology, University Medical Center Mainz, Mainz, Germany.
authors.forename: Annette
authors.initials: A
authors.lastname: Schröder
authors.affiliation: Mediconomics GmbH, Hannover, Germany.
authors.forename: Uwe
authors.initials: U
authors.lastname: Albrecht
authors.affiliation: Institute of Applied Statistics, Bielefeld, Germany.
authors.forename: Jörg
authors.initials: J
authors.lastname: Schnitker
authors.affiliation: KontinenzZentrum Hirslanden, Zürich, Switzerland.
authors.forename: André
authors.initials: A
authors.lastname: Reitz
authors.affiliation: Division of Pediatric Urology, Department of Urology, University Medical Center Mainz, Mainz, Germany.
authors.forename: Raimund
authors.initials: R
authors.lastname: Stein
mesh_terms: D000283:Administration, Intravesical; D000284:Administration, Oral; D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008333:Mandelic Acids / Q000008:administration & dosage*; D011446:Prospective Studies; D012996:Solutions; D016896:Treatment Outcome; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D064804:Urological Agents / Q000008:administration & dosage*
chemical_list: D008333:Mandelic Acids; D012996:Solutions; D064804:Urological Agents; C005419:oxybutynin
keywords: bladder capacity; catheterization; neurogenic detrusor; randomized clinical trial; ready-to use oxybutynin